Clinical Trial Update: Observational Study of ASCVD Risks of Type 2 Diabetes in East China

View source ↗

Summary

This completed observational study in East China examines ASCVD risk in individuals with type 2 diabetes, with data related to liraglutide exposure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Zhejiang Provincial People's Hospital | Conditions: Type 2 Diabetes Mellitus, Arteriosclerotic Cardiovascular Disease | Status: COMPLETED